| 2025-04-23 |
OBI Pharma, Inc |
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science. obipharma.com ↗ |
| 2024-03-11 |
OBI Pharma, Inc |
OBI announces the termination of OBI-3424 Phase II trial obipharma.com ↗ |
| 2022-06-06 |
OBI Pharma, Inc |
Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424 obipharma.com ↗ |
| 2022-05-17 |
OBI Pharma, Inc |
OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth obipharma.com ↗ |
| 2022-04-08 |
OBI Pharma, Inc |
Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science obipharma.com ↗ |
| 2022-04-07 |
OBI Pharma, Inc |
OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science obipharma.com ↗ |
| 2022-01-25 |
OBI Pharma, Inc |
OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424 obipharma.com ↗ |
| 2021-04-26 |
OBI Pharma, Inc |
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL obipharma.com ↗ |
| 2021-04-11 |
OBI Pharma, Inc |
Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4 obipharma.com ↗ |
| 2021-04-06 |
OBI Pharma, Inc |
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4 obipharma.com ↗ |
| 2020-05-29 |
OBI Pharma, Inc |
OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424 obipharma.com ↗ |
| 2020-05-20 |
OBI Pharma, Inc |
OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424 obipharma.com ↗ |
| 2018-09-19 |
OBI Pharma, Inc |
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL) obipharma.com ↗ |
| 2018-08-27 |
Ascentawits Pharmaceuticals, Ltd |
【要闻】艾欣达伟抗癌新药AST-3424（OBI-3424）获得FDA核准进入 I/II期临床试验 ascentawits.com ↗ |
| 2018-07-08 |
OBI Pharma, Inc |
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC) obipharma.com ↗ |
| 2018-04-19 |
OBI Pharma, Inc |
OBI Pharma Announces FDA Clearance of OBI-3424 IND Application for A Phase I/II Study Targeting AKR1C3 Solid Tumors obipharma.com ↗ |
| 2017-10-30 |
OBI Pharma, Inc |
OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics obipharma.com ↗ |
| 2017-10-24 |
OBI Pharma, Inc |
OBI Pharma Announces Presentation on OBI-3424 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics obipharma.com ↗ |
|